NCT02190604 - Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Cystic Fibrosis

Interventions

DRUG

Placebo

Capsule- oral dose

DRUG

QBW251

Capsule - oral dose

Trial Locations (23)

4

Novartis Investigative Site, Dublin

1090

Novartis Investigative Site, Brussels

9000

Novartis Investigative Site, Ghent

10098

Novartis Investigative Site, Berlin

27514

Novartis Investigative Site, Chapel Hill

34059

Novartis Investigative Site, Montpellier

40202

Novartis Investigative Site, Louisville

43205

Novartis Investigative Site, Columbus

50937

Novartis Investigative Site, Cologne

60611

Novartis Investigative Site, Chicago

63110

Novartis Investigative Site, St Louis

69495

Novartis Investigative Site, Pierre-Bénite

75014

Novartis Investigative Site, Paris

80206

Novartis Investigative Site, Denver

35294-0006

Novartis Investigative Site, Birmingham

02114

Novartis Investigative Site, Boston

02115

Novartis Investigative Site, Boston

050159

Novartis Investigative Site, Bucharest

EH54 6PP

Novartis Investigative Site, Livingston

BT9 7AB

Novartis Investigative Site, Belfast

SW 6NP

Novartis Investigative Site, London

M23 9QZ

Novartis Investigative Site, Manchester

CF484DR

Novartis Investigative Site, Mid Glamorgan